Category Archives: Uncategorized

Will the Trump tariffs on China raise drug prices for Americans?

by Ed Silverama, StatNews | April 4, 2018 Now that the Trump administration has proposed 25 percent tariffs on thousands of Chinese-made products, including raw ingredients for a slew of medicines, there are concerns that prices for these products may rise, … Continue reading

Posted in Drug prices, Generics, Uncategorized | Leave a comment

Dutch hospital challenges big pharma by making own version of very pricey drug

by Robin Pascoe, The Dutch News | April 5, 2018 Amsterdam’s AMC teaching hospital is to start making its own version of a licenced drug to treat a rare metabolic disorder because the medicine is no longer covered by health insurance … Continue reading

Posted in Bad Pharma, Drug prices, Uncategorized | Leave a comment

India’s ailing battle against TB: One in five multidrug-resistant patients do not complete treatment

By Swagata Yadava, FirstPost | April 10, 2018 New Delhi: Nearly one in five multidrug-resistant (MDR) tuberculosis (TB) patients put on treatment in the public sector were lost to follow-up (LFU). This means that they either did not start treatment or … Continue reading

Posted in Tuberculosis (TB), Uncategorized | Leave a comment

Why do new medicines cost so much, and what can we do about it?

  The cost of new drugs is putting increasing pressure on people in both rich and poor countries. We explain why it’s a burning issue by Sarah Boseley Health editor Why does it matter what medicines cost? If you are lucky enough … Continue reading

Posted in Doha Declaration, Patent, R&D, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

Less than four percent of private investment in health R&D targets the developing world

by Liz Sablich, Brookings  A recent report published by the Brookings Private Sector Global Health R&D Project found that the private sector devotes at least $159.9 billion to investments related to health research and development (R&D) annually. That total includes $156.7 billion from … Continue reading

Posted in R&D, Uncategorized | Leave a comment

The Power of TRIPS Flexibilities in Medicines Procurement

Source: Medicine Law & Policy The government of Malaysia has began to roll out treatment of people infected with the hepatitis C virus (HCV).  Treatment will be a combination of antivirals (sofosbuvir and daclatasvir) from generic producers, including the Egyptian company … Continue reading

Posted in Compulsory Licensing, TRIPS flexibilities, Uncategorized | Leave a comment

MSF statement on resumption of EU-India FTA negotiations

Source: MSF Access Campaign | 11 April 2018 Officials from the European Union (EU) and India are expected to meet in Brussels on April 12th to resume technical talks on the long-stalled EU-India free trade agreement (FTA). A leaked draft … Continue reading

Posted in EU-India FTA, IPR, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized, WTO | Leave a comment